GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » Retained Earnings

GeneTether Therapeutics (XCNQ:GTTX) Retained Earnings : C$-5.75 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. GeneTether Therapeutics's retained earnings for the quarter that ended in Dec. 2023 was C$-5.75 Mil.

GeneTether Therapeutics's quarterly retained earnings declined from Jun. 2023 (C$-5.23 Mil) to Sep. 2023 (C$-5.37 Mil) and declined from Sep. 2023 (C$-5.37 Mil) to Dec. 2023 (C$-5.75 Mil).

GeneTether Therapeutics's annual retained earnings declined from Dec. 2021 (C$-2.41 Mil) to Dec. 2022 (C$-4.88 Mil) and declined from Dec. 2022 (C$-4.88 Mil) to Dec. 2023 (C$-5.75 Mil).


GeneTether Therapeutics Retained Earnings Historical Data

The historical data trend for GeneTether Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics Retained Earnings Chart

GeneTether Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Retained Earnings
-0.31 -2.41 -4.88 -5.75

GeneTether Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.88 -5.20 -5.23 -5.37 -5.75

GeneTether Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


GeneTether Therapeutics  (XCNQ:GTTX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


GeneTether Therapeutics (XCNQ:GTTX) Business Description

Traded in Other Exchanges
N/A
Address
301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3
GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (XCNQ:GTTX) Headlines

No Headlines